Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis)

被引：6

作者：

Pongratz, Dieter

机构：

[1] Univ Munich, Fak Med, Friedrich Baur Inst, Neurol Klin & Poliklin, D-80336 Munster, Germany

[2] Hochrhein Inst, Dept Klin Forsch, D-79713 Bad Sackingen, Germany

来源：

JOURNAL OF NEUROLOGY | 2006年 / 253卷 / Suppl 5期

关键词：

dermatomyositis; polymyositis; inclusion body myositis; corticosteroids; immunosuppressives; intravenous immunoglobulins;

D O I：

10.1007/s00415-006-5010-2

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Polymyositis, dermatomyositis, and inclusion body myositis are idiopathic inflammatory myopathies of unknown etiology with autoimmune pathogenesis. For choosing an individual and efficient therapy, diagnostic assignment is an important factor. Therapeutic options in dermatomyositis and polymyositis include corticosteroids and immunosuppressives. Intravenous immunoglobulins are only needed in special cases. In inclusion body myositis, corticosteroids and immunosuppressives are not successful. At the moment intravenous immunoglobulins are the only therapeutic possibility.

引用

页码：64 / 65

页数：2

共 50 条

[31] OVERVIEW AND CLINICAL MANIFESTATIONS OF INFLAMMATORY MYOSITIS - POLYMYOSITIS AND DERMATOMYOSITIS
STRONGWATER, SL
[J]. MOUNT SINAI JOURNAL OF MEDICINE, 1988, 55 (06): : 435 - 446
[32] Sporadic inclusion body myositis -: etiology, pathogenesis and therapeutic options
Walter, MC
Lochmüller, H
Pongratz, D
[J]. NERVENHEILKUNDE, 2003, 22 (03) : 142 - 145
[33] Polymyositis, dermatomyositis and inclusion-body myositis - Critical overview of current criteria in diagnosis and therapy
Krajnc, I
Gorisek, B
[J]. AKTUELLE RHEUMATOLOGIE, 1997, 22 (04) : 123 - 130
[34] Granulysin expression in polymyositis and inclusion body myositis
Ikezoe, Koji
Oshima, Sachiko
Osoegawa, Manabu
Tanaka, Masato
Ogawa, Kazuyuki
Nagata, Kinya
Kira, Jun-ichi
[J]. NEUROMUSCULAR DISORDERS, 2006, 16 : S87 - S87
[35] Diffusion-weighted imaging of inflammatory myopathies: Polymyositis and dermatomyositis
Qi, Jing
Olsen, Nancy J.
Price, Ronald R.
Winston, Jason A.
Park, Jane H.
[J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2008, 27 (01) : 212 - 217
[36] Established and new treatments of the idiopathic inflammatory myopathies: dermatomyositis and polymyositis
Pipitone, N.
Salvarani, C.
[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2007, 25 (06) : 896 - 906
[37] Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis
Dalakas, MC
[J]. NEUROLOGY, 1998, 51 (06) : S37 - S45
[38] MR-IMAGING AND P-31 MR SPECTROSCOPY FOR QUANTITATIVE COMPARISON OF INFLAMMATORY MYOPATHIES - DERMATOMYOSITIS, POLYSYOSITIS, AND INCLUSION BODY MYOSITIS
PARK, JH
OLSEN, NJ
VITAL, T
GILPIN, L
PRICE, RR
[J]. RADIOLOGY, 1992, 185 : 322 - 322
[39] An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis - Studies in three families
Sivakumar, K
SeminoMora, C
Dalakas, MC
[J]. BRAIN, 1997, 120 : 653 - 661
[40] Plasma cells in muscle in inclusion body myositis and polymyositis
Greenberg, SA
Bradshaw, EM
Pinkus, JL
Pinkus, GS
Burleson, T
O'Connor, KC
Amato, AA
[J]. ANNALS OF NEUROLOGY, 2005, 58 : S38 - S38

← 1 2 3 4 5 →